
Chinese pharmaceutical company registered on 12 October 2005 with the Chengdu administration for industry and commerce in Sichuan, with Sun Yi as legal representative. Has grown into a globally oriented full industry chain group built around innovative medicines with total assets of close to two billion yuan, seven wholly owned subsidiaries and one controlled subsidiary covering research, manufacturing and international and domestic sales, and more than twelve hundred employees. Concentrates on the central nervous system, oncology, autoimmune disease and anti-ageing, holds a hundred and five granted Chinese and international patents and develops products across cardio-cerebrovascular, oncology and immunology, with its exclusive patented product ginkgolide injection sold as Jingelai entering the national reimbursement list in July 2017.
Bewertung hinterlassen